Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Taxes (2024 - 2025)

BridgeBio Pharma's Current Taxes history spans 2 years, with the latest figure at $2.1 million for Q2 2025.

  • For Q2 2025, Current Taxes changed N/A year-over-year to $2.1 million; the TTM value through Jun 2025 reached $2.1 million, changed N/A, while the annual FY2024 figure was $1.2 million, N/A changed from the prior year.
  • Current Taxes for Q2 2025 was $2.1 million at BridgeBio Pharma, up from $1.2 million in the prior quarter.
  • Across five years, Current Taxes topped out at $2.1 million in Q2 2025 and bottomed at $1.2 million in Q4 2024.